All News
Filter News
Found 806,088 articles
-
Soft Tissue Repair Market Size to Hit USD 21.2 Billion by 2030
10/3/2022
According to Nova one advisor, the global Soft Tissue Repair market was valued at USD 10.7 billion in 2022 and it is expected to hit around USD 21.2 billion by 2030 with a CAGR of 7.7% during the forecast period 2022 to 2030.
-
Regulatory Affairs Outsourcing Market Size to Hit USD 13.85 Bn by 2030
10/3/2022
According to Nova one advisor, the global Regulatory Affairs Outsourcing market size is expected to hit around USD 13.85 billion by 2030 from valued at USD 6.20 billion in 2021 and growing at a CAGR of 8.40% from 2022 to 2030.
-
Pharmacovigilance Market Size, Growth, Demand, Opportunities & Forecast To 2030
10/3/2022
Latest Study on “Pharmacovigilance Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
-
Nanotechnology Drug Delivery Market Size to Hit USD 150.8 Bn by 2030
10/3/2022
According to Nova one advisor, the global Nanotechnology Drug Delivery market size is expected to hit around USD 150.8 billion by 2030 from valued at USD 80.1 billion in 2021 and growing at a CAGR of 10.9% from 2022 to 2030.
-
Nanomedicine Market Size to Hit USD 964.25 Billion by 2030
10/3/2022
According to Nova one advisor, the global Nanomedicine market size is expected to hit around USD 964.25 billion by 2030 from valued at USD 377.40 billion in 2021 and growing at a CAGR of 11.14% from 2022 to 2030.
-
Forensic Technologies Market Size to Hit USD 90.8 Billion by 2030
10/3/2022
According to Nova one advisor, the global Forensic Technologies market size is expected to hit around USD 90.8 billion by 2030 from valued at USD 52.28 billion in 2021 and growing at a CAGR of 15.2% from 2022 to 2030.
-
Endoscopic Retrograde Cholangiopancreatography Market Size to Surpass USD 4.0 Bn by 2030
10/3/2022
The global Endoscopic Retrograde Cholangiopancreatography market size was estimated at USD 1.9 billion in 2022 and is expected to surpass around USD 4.0 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.6% during the forecast period 2022 to 2030.
-
Bioinformatics Market Size, Growth, Demand, Opportunities & Forecast To 2030
10/3/2022
The global Bioinformatics market size is expected to be worth around USD 45.9 billion by 2030, according to a new report by Nova one advisor.
-
Collagen Market Size to Hit USD 21.4 Billion by 2030
10/3/2022
According to Nova one advisor, the global Collagen market size is expected to hit around USD 21.4 billion by 2030 from valued at USD 10.5 billion in 2021 and growing at a CAGR of 9.2% from 2022 to 2030.
-
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
10/2/2022
Mesoblast Limited announced that it has submitted to the U.S. Food and Drug Administration substantial new information on clinical and potency assay items identified in the Complete Response Letter received from FDA in September 2020 to the Biologics License Application for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.
-
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
10/2/2022
Myovant Sciences Ltd. confirmed that it has received a preliminary, non-binding proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash.
-
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
10/2/2022
Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society of America Annual Scientific Meeting 2022.
-
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
10/2/2022
Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS.
-
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
10/2/2022
Cytokinetics, Incorporated announced new data on symptom improvement and quality of life related to treatment with aficamten in REDWOOD-HCM OLE in a Late Breaking Clinical Trials session at the Heart Failure Society of America Annual Scientific Meeting in Washington, D.C.
-
Humana significantly expands Medicare Advantage health plan offerings in 2023 with focus on greater value for members
10/1/2022
Humana Inc. released details of its Medicare Advantage and Medicare Prescription Drug Plan offerings for 2023 – with a clear focus on benefits and support based on what its members have said they want and need.
-
Rare Disease PTEN Hamartoma Tumour Syndrome (PHTS) Granted International Classification of Diseases (ICD) Code
10/1/2022
PTEN Research Foundation announced that the rare genetic disease, PHTS, has been given a new and unique disease code in the International Classification of Diseases revision 10, Clinical Modification system that is managed by the US Center for Disease Control and Prevention.
-
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
10/1/2022
Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2022.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 01, 2022
10/1/2022
Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.
-
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
10/1/2022
Belite Bio, Inc presented one-year data from their ongoing two-year Phase 2 clinical study of Tinlarebant in STGD1 as part of the oral presentation series at the Annual Meeting of the American Academy of Ophthalmology held during September 30 - October 3, 2022 at McCormick Place, Chicago.
-
Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
10/1/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the primary results from the Phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec in patients with the inherited retinal disease X-linked retinitis pigmentosa associated with the retinitis pigmentosa GTPase regulator gene.